Llwytho...
Macitentan in pulmonary arterial hypertension: The SERAPHIN trial
Major limitations of pulmonary arterial hypertension (PAH) drug trials include the small number of enrolled patients, short term follow up (12-16 weeks), and lack of morbidity and mortality primary endpoints. The recently published SERAPHIN (Study with an Endothelin Receptor Antagonist in Pulmonary...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Glob Cardiol Sci Pract |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Bloomsbury Qatar Foundation Journals
2014
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4220429/ https://ncbi.nlm.nih.gov/pubmed/25405173 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5339/gcsp.2014.20 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|